statistiche ricercatore

Continente	#
NA - Nord America	642
AS - Asia	530
EU - Europa	332
SA - Sud America	104
Continente sconosciuto - Info sul continente non disponibili	12
AF - Africa	10
OC - Oceania	1
Totale	1.631

Nazione	#
US - Stati Uniti d'America	574
SG - Singapore	231
RU - Federazione Russa	143
CN - Cina	126
BR - Brasile	78
VN - Vietnam	69
IT - Italia	67
CA - Canada	40
HK - Hong Kong	34
GB - Regno Unito	24
BD - Bangladesh	23
FI - Finlandia	20
DE - Germania	19
SE - Svezia	18
MX - Messico	13
FR - Francia	12
IN - India	11
AR - Argentina	8
PL - Polonia	7
TR - Turchia	7
CO - Colombia	6
JP - Giappone	6
ES - Italia	5
ID - Indonesia	5
LT - Lituania	5
ZA - Sudafrica	4
AT - Austria	3
CW - ???statistics.table.value.countryCode.CW???	3
IQ - Iraq	3
PR - Porto Rico	3
CL - Cile	2
CR - Costa Rica	2
EC - Ecuador	2
EG - Egitto	2
GP - Guadalupe	2
GT - Guatemala	2
IE - Irlanda	2
PE - Perù	2
PK - Pakistan	2
PY - Paraguay	2
UA - Ucraina	2
VE - Venezuela	2
AU - Australia	1
AZ - Azerbaigian	1
BB - Barbados	1
BY - Bielorussia	1
CU - Cuba	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
EE - Estonia	1
GE - Georgia	1
GY - Guiana	1
IL - Israele	1
IR - Iran	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
LB - Libano	1
LK - Sri Lanka	1
MA - Marocco	1
ML - Mali	1
MY - Malesia	1
NI - Nicaragua	1
NL - Olanda	1
NP - Nepal	1
OM - Oman	1
PH - Filippine	1
RS - Serbia	1
SV - El Salvador	1
TH - Thailandia	1
TN - Tunisia	1
UY - Uruguay	1
Totale	1.622

Nome	#
Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction	219
Bridging Atrial and Ventricular Failure Through Biomarkers	219
Sudden Cardiac Death in Heart Failure: A 20-Year Perspective From a Mediterranean Cohort	216
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	181
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?	169
Biomarkers of inflammation in heart failure: from risk prediction to possible treatment targets	168
Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions	158
Reply to the letter regarding the article ‘Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines’	157
Different Effects on Protein Expression of CDR132L, an Antisense Inhibitor of miR-132, and Standard Therapies for Myocardial Infarction	144
Totale	1.631

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2024/2025	410	10	8	23	7	24	15	67	103	40	27	60	26
2025/2026	1.068	73	114	90	220	142	98	75	33	42	68	62	51
2026/2027	153	14	24	53	62	0	0	0	0	0	0	0	0
Totale													1.631